A Study of CTX-4430 in Patients with Cystic Fibrosis

• Research type

  Research Study

• Full title

  A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 when Administered Orally to Cystic Fibrosis Patients for Fifteen Days

• IRAS ID

  136015

• Contact name

  J. Stuart Elborn

• Contact email

  s.elborn@qub.ac.uk

• Sponsor organisation

  Celtaxsys, Inc

• Eudract number

  2013-001593-25

• REC name

  HSC REC A

• REC reference

  13/NI/0106

• Date of REC Opinion

  22 Aug 2013

• REC opinion

  Further Information Favourable Opinion